MoonLake Immunotherapeutics (MLTX) Research & Development (2021 - 2026)

MoonLake Immunotherapeutics' Research & Development history runs 6 years deep, the most recent figure standing at $54.5 million for Q1 2026.

• In Q1 2026, Research & Development rose 49.52% year-over-year to $54.5 million; the TTM figure through Mar 2026 stood at $220.9 million (up 62.18% YoY), while the FY2025 annual figure was $202.9 million, up 79.89% from the prior year.
• Research & Development was $54.5 million for Q1 2026 at MoonLake Immunotherapeutics, down from $56.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $60.6 million in Q3 2025 to a low of $7.4 million in Q1 2023.
• Historically, Research & Development has averaged $26.1 million across 5 years, with a median of $13.0 million in 2024.
• Biggest YoY gain for Research & Development was 1247.88% in 2022; the steepest drop was 68.0% in 2022.
• A 5-year view of Research & Development shows it stood at $11.4 million in 2022, then dropped by 28.77% to $8.1 million in 2023, then jumped by 398.39% to $40.4 million in 2024, then soared by 38.77% to $56.0 million in 2025, then decreased by 2.66% to $54.5 million in 2026.
• The last three Research & Development figures came in at $54.5 million (Q1 2026), $56.0 million (Q4 2025), and $60.6 million (Q3 2025), per Business Quant data.